{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:48:02Z","timestamp":1776426482939,"version":"3.51.2"},"reference-count":78,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cystic fibrosis (CF) is a multisystem disease. This article provides an up-to-date review of many of the nonrespiratory complications of CF, including mental health issues, nutritional and gastrointestinal problems, fertility issues, diabetes mellitus, bone health and musculoskeletal problems, liver disease, renal problems, and risk of malignancy. It highlights the recent impact of new therapies, including CF transmembrane conductance regulator modulators, on the nonrespiratory complications of CF and provides insights into the potential challenges faced by an aging population of adults with CF and their caregivers, including the potential future risk for cardiovascular disease.<\/jats:p>","DOI":"10.1055\/s-0042-1758734","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T01:12:54Z","timestamp":1671498774000},"page":"307-314","source":"Crossref","is-referenced-by-count":12,"title":["Beyond the Lungs\u2014Emerging Challenges in Adult Cystic Fibrosis Care"],"prefix":"10.1055","volume":"44","author":[{"given":"Siobhain","family":"Mulrennan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia"},{"name":"Faculty of Health and Medical Sciences, University of Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karuna","family":"Sapru","sequence":"additional","affiliation":[{"name":"Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Tewkesbury","sequence":"additional","affiliation":[{"name":"Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"d1008","DOI":"10.1136\/bmj.d1008","article-title":"Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007","volume":"342","author":"P M George","year":"2011","journal-title":"BMJ"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1183\/09031936.00119714","article-title":"A contemporary survival analysis of individuals with cystic fibrosis: a cohort study","volume":"45","author":"A L Stephenson","year":"2015","journal-title":"Eur Respir J"},{"issue":"19","key":"ref3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"P G Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/thoraxjnl-2020-215556","article-title":"Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study","volume":"76","author":"R M Mitchell","year":"2021","journal-title":"Thorax"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"M C Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"09","key":"ref6","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","volume":"39","author":"A Bonhoure","year":"2020","journal-title":"Clin Nutr"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"D Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"17834","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"C Y Ooi","year":"2018","journal-title":"Sci Rep"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MPG.0000000000001788","article-title":"Reduction of recurrence risk of pancreatitis in cystic fibrosis with ivacaftor: case series","volume":"66","author":"A Carrion","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11894-017-0546-0","article-title":"The enigmatic gut in cystic fibrosis: linking inflammation, dysbiosis, and the increased risk of malignancy","volume":"19","author":"M Garg","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2016.07.011","article-title":"Cancer risk among lung transplant recipients with cystic fibrosis","volume":"16","author":"A K Fink","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2017.12.012","article-title":"Cystic fibrosis colorectal cancer screening consensus recommendations","volume":"154","author":"D Hadjiliadis","year":"2018","journal-title":"Gastroenterology"},{"issue":"32","key":"ref13","first-page":"4179","article-title":"CFTR is a tumor suppressor gene in murine and human intestinal cancer","volume":"35","author":"B LN Than","year":"2016","journal-title":"Oncogene"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jcf.2016.01.002","article-title":"Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis","volume":"15","author":"D E Niccum","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12876-019-0979-z","article-title":"A non-randomised single centre cohort study, comparing standard and modified bowel preparations, in adults with cystic fibrosis requiring colonoscopy","volume":"19","author":"A G Matson","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"S 02","key":"ref17","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"A Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/ajrccm.162.3.9904075","article-title":"Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline","volume":"162","author":"C E Milla","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"S 02","key":"ref19","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","article-title":"Cystic fibrosis related diabetes: medical management","volume":"18","author":"K L Ode","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"S 02","key":"ref20","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcf.2019.08.025","article-title":"Continuous glucose monitoring in cystic fibrosis\u2014a practical guide","volume":"18","author":"C L Chan","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jcf.2008.12.001","article-title":"Use of the insulin pump in treat cystic fibrosis related diabetes","volume":"8","author":"D S Hardin","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/dia.2021.0354","article-title":"The effect of control IQ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis-related diabetes","volume":"24","author":"K J Scully","year":"2022","journal-title":"Diabetes Technol Ther"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jcf.2019.08.002","article-title":"Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: a pilot study","volume":"19","author":"J S Sherwood","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"L Bessonova","year":"2018","journal-title":"Thorax"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"K J Scully","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jcf.2012.11.012","article-title":"Left ventricular and aortic dysfunction in cystic fibrosis mice","volume":"12","author":"Z M Sellers","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1378\/chest.12-2444","article-title":"Joining the crowd: cystic fibrosis and cardiovascular disease risk factors","volume":"143","author":"C E Cross","year":"2013","journal-title":"Chest"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00044009","article-title":"Increased augmentation index in patients with cystic fibrosis","volume":"34","author":"J H Hull","year":"2009","journal-title":"Eur Respir J"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1378\/chest.12-1934","article-title":"Evidence of vascular endothelial dysfunction in young patients with cystic fibrosis","volume":"143","author":"S Poore","year":"2013","journal-title":"Chest"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.freeradbiomed.2014.08.005","article-title":"Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis","volume":"76","author":"E J Reverri","year":"2014","journal-title":"Free Radic Biol Med"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcf.2009.09.002","article-title":"Prevalence of dyslipidemia in adults with cystic fibrosis","volume":"9","author":"B Rhodes","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/MPG.0000000000002694","article-title":"Cystic fibrosis-related liver disease is associated with increased disease burden and endocrine comorbidities","volume":"70","author":"H Singh","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"17421","DOI":"10.1038\/s41598-020-74502-1","article-title":"Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry","volume":"10","author":"A Earnest","year":"2020","journal-title":"Sci Rep"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jcf.2019.09.016","article-title":"Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: a longitudinal prospective birth cohort study","volume":"19","author":"M Cipolli","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome","volume":"36","author":"C Colombo","year":"2002","journal-title":"Hepatology"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients","volume":"69","author":"P Y Bo\u00eblle","year":"2019","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"D Debray","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jcmgh.2019.04.013","article-title":"Pathophysiology of cystic fibrosis liver disease: a channelopathy leading to alterations in innate immunity and in microbiota","volume":"8","author":"R Fiorotto","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.cgh.2018.10.046","article-title":"Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension","volume":"17","author":"H Wu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1053\/j.gastro.2011.06.052","article-title":"Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-\u03baB-mediated inflammatory response in mice","volume":"141","author":"R Fiorotto","year":"2011","journal-title":"Gastroenterology"},{"key":"ref41","first-page":"101553","article-title":"Delayed hepatic necrosis in a cystic fibrosis patient taking elexacaftor\/tezacaftor\/ivacaftor (Kaftrio)","volume":"34","author":"M Salehi","year":"2021","journal-title":"Respir Med Case Rep"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcf.2021.07.018","article-title":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","volume":"21","author":"D Drummond","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1574886317666220513105114","article-title":"Changes in share wave elastography after lumacaftor\/ivacaftor treatment in children with cystic fibrosis","volume":"18","author":"A Kanavaki","year":"2023","journal-title":"Curr Drug Saf"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1164\/rccm.201105-0932OC","article-title":"Risk factors for chronic kidney disease in adults with cystic fibrosis","volume":"184","author":"B S Quon","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jcf.2013.03.005","article-title":"A review of renal disease in cystic fibrosis","volume":"12","author":"D Nazareth","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s001980200007","article-title":"Abnormal bone turnover in cystic fibrosis adults","volume":"13","author":"R M Aris","year":"2002","journal-title":"Osteoporos Int"},{"key":"ref47","first-page":"2","article-title":"Bone health and disease in cystic fibrosis","volume":"20","author":"M Marquette","year":"2016","journal-title":"Paediatr Respir Rev"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/thx.2006.075887","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone","volume":"62","author":"E F Shead","year":"2007","journal-title":"Thorax"},{"issue":"02","key":"ref49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcf.2009.11.007","article-title":"Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis","volume":"9","author":"E F Shead","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"03","key":"ref50","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bone.2004.05.009","article-title":"Prevalence and correlates of vertebral fractures in adults with cystic fibrosis","volume":"35","author":"M Rossini","year":"2004","journal-title":"Bone"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1378\/chest.130.2.539","article-title":"Prevalence of vertebral fractures in adults with cystic fibrosis and their relationship to bone mineral density","volume":"130","author":"A Stephenson","year":"2006","journal-title":"Chest"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-128-3-199802010-00004","article-title":"Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis","volume":"128","author":"R M Aris","year":"1998","journal-title":"Ann Intern Med"},{"issue":"S 02","key":"ref53","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jcf.2019.08.017","article-title":"Cystic fibrosis bone disease treatment: current knowledge and future directions","volume":"18","author":"M S Putman","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jcf.2016.09.003","article-title":"Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation","volume":"15","author":"I Sermet-Gaudelus","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"03","key":"ref55","doi-asserted-by":"crossref","first-page":"e1248","DOI":"10.1210\/clinem\/dgaa890","article-title":"The effects of ivacaftor on bone density and microarchitecture in children and adults with cystic fibrosis","volume":"106","author":"M S Putman","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/ppul.24290","article-title":"Assessing arthritis in the context of cystic fibrosis","volume":"54","author":"E A Clarke","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/HUMREP\/11.3.513","article-title":"Cystic fibrosis mutation screening in healthy men with reduced sperm quality","volume":"11","author":"K van der Ven","year":"1996","journal-title":"Hum Reprod"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2018.10.009","article-title":"Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age","volume":"18","author":"M Shteinberg","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"341","key":"ref60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.morpho.2018.11.001","article-title":"Update on the cellular and molecular aspects of cystic fibrosis transmembrane conductance regulator (CFTR) and male fertility","volume":"103","author":"M Yefimova","year":"2019","journal-title":"Morphologie"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"K E O'Connor","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.contraception.2020.02.006","article-title":"Contraceptive use among women with cystic fibrosis: a pilot study linking reproductive health questions to the Cystic Fibrosis Foundation National Patient Registry","volume":"101","author":"E M Godfrey","year":"2020","journal-title":"Contraception"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10815-019-01635-2","article-title":"Universal strategy for preimplantation genetic testing for cystic fibrosis based on next generation sequencing","volume":"37","author":"S Chamayou","year":"2020","journal-title":"J Assist Reprod Genet"},{"issue":"03","key":"ref64","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201211-108OC","article-title":"Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis","volume":"10","author":"M S Schechter","year":"2013","journal-title":"Ann Am Thorac Soc"},{"issue":"13","key":"ref65","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/1471-0528.16423","article-title":"The outcome of pregnancy in women with cystic fibrosis: a UK population-based descriptive study","volume":"127","author":"A Ashcroft","year":"2020","journal-title":"BJOG"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcf.2020.09.002","article-title":"Baseline cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression","volume":"20","author":"M Cohen-Cymberknoh","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcf.2019.06.003","article-title":"Pregnancy outcome in women with cystic fibrosis and poor pulmonary function","volume":"19","author":"Q Reynaud","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref68","doi-asserted-by":"crossref","first-page":"1901208","DOI":"10.1183\/13993003.01208-2019","article-title":"ERS\/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases","volume":"55","author":"P G Middleton","year":"2020","journal-title":"Eur Respir J"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2017.11.009","article-title":"Drugs during pregnancy and breast feeding in women diagnosed with cystic fibrosis\u2014an update","volume":"17","author":"M AGM Kroon","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"J L Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"04","key":"ref71","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators\u2014an international survey","volume":"19","author":"E F Nash","year":"2020","journal-title":"J Cyst Fibros"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jcf.2007.10.001","article-title":"Guidelines for the management of pregnancy in women with cystic fibrosis","volume":"7","author":"F P Edenborough","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"12","key":"ref73","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries","volume":"69","author":"A L Quittner","year":"2014","journal-title":"Thorax"},{"issue":"12","key":"ref74","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/ppul.22990","article-title":"Depression, illness severity, and healthcare utilization in cystic fibrosis","volume":"49","author":"C Snell","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"05","key":"ref75","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1037\/hea0000136","article-title":"Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis","volume":"34","author":"M E Hilliard","year":"2015","journal-title":"Health Psychol"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1378\/chest.06-2474","article-title":"The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis","volume":"132","author":"K A Riekert","year":"2007","journal-title":"Chest"},{"issue":"09","key":"ref77","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1503\/cmaj.130403","article-title":"Recommendations on screening for depression in adults","volume":"185","author":"M Joffres","year":"2013","journal-title":"CMAJ"},{"issue":"01","key":"ref78","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","article-title":"International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety","volume":"71","author":"A L Quittner","year":"2016","journal-title":"Thorax"},{"issue":"02","key":"ref79","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"21","author":"S Heo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref80","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"G Spoletti","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T01:29:07Z","timestamp":1678411747000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":78,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758734","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]}}}